Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafluprost for Residual Glaucoma Post-Trabeculectomy
NCT03595865Unknown
- Start
- Aug 2018
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
01
Overview
Open-label trial of tafluprost in primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG) (2 arms). Primary endpoint: Intraocular Pressure at 6 months. Status: unknown.
02
Drugs
tafluprost
03
Conditions
primary open-angle glaucoma (POAG)primary angle-closure glaucoma (PACG)
Beyond the preview
Go deeper on NCT03595865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595865.